


**Product Name** : Glecirasib  
**Cat. No.** : PC-22626  
**CAS No.** : 2657613-87-9  
**Molecular Formula** : C<sub>31</sub>H<sub>26</sub>ClF<sub>4</sub>N<sub>7</sub>O<sub>2</sub>  
**Molecular Weight** : 640.04  
**Target** : Ras  
**Solubility** : 10 mM in DMSO



CAS: 2657613-87-9

## Biological Activity

Glecirasib (JAB-21822) is a highly selective, covalent oral **KRAS G12C** inhibitor with IC<sub>50</sub> of 1.6 nM (SOS1-mediated guanine nucleotide exchange, GDP- KRAS G12C) and IC<sub>50</sub> of 7.3 nM in Phospho-ERK inhibition assay in NCI-H358 cells. Glecirasib (JAB-21822) potently inhibits cell viability in NCI-H358 cells with IC<sub>50</sub> of 23 nM. Glecirasib (JAB-21822) inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation of KRAS upon stimulation of upstream signaling factors.

## References

- Jian Li, et al. 2024 ASCO. Volume 42, Number 3\_suppl.
- Li A, et al. *J Med Chem*. 2025 Jan 28. doi: 10.1021/acs.jmedchem.4c02939.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com